Docket Room
HB 2246·TN·house

Health Care - As enacted, authorizes a physician to perform stem cell therapy or regenerative medicine therapy that is not approved by the United States food and drug administration if such therapy is used for a treatment or procedure that is within the scope of practice of the physician; makes related changes. - Amends TCA Title 63 and Title 68.

Signed into LawFiled Feb 2, 2026
Sponsor: Hurt
Latest Action

Pub. Ch. 1016

May 26, 2026

Summary

The law lets a licensed physician use stem cell or regenerative medicine treatments that the FDA has not approved, as long as the procedure is within the physician’s scope of practice and relates to orthopedics, wound care, or pain management. The stem cells must come from FDA‑registered or accredited facilities, and physicians must provide a clear notice and obtain patient consent. The measure updates Tennessee’s health‑care statutes to define terms and set these requirements.

AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.

Share

Track this bill

Get real-time alerts when HB 2246 changes status, plus AI-powered summaries and stage predictions.

Sign up free
Docket Room · Nonpartisan legislative tracking
Docket Room IntelligencePro

Ask about your legislation

I can analyze your tracked bills, upcoming hearings, and recent changes.

AI-generated · Nonpartisan · Not legal advice